- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | NeOnc Technologies Holdings GAAP EPS of -$0.45 | 1 | Seeking Alpha | ||
| 14.11. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update | 240 | GlobeNewswire (Europe) | CALABASAS, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies... ► Artikel lesen | |
| 14.11. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 13.11. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High-Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026) | 128 | GlobeNewswire (Europe) | CALABASAS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering... ► Artikel lesen | |
| NEONC TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 06.11. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 04.11. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth | 1 | GlobeNewswire (USA) | ||
| 30.10. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.10. | NeOnc Technologies Holdings, Inc.: His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies' Subsidiary, NuroMENA, Pioneering UAE-US Partnership in Brain Cancer Treatment | 174 | GlobeNewswire (Europe) | CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 28, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical... ► Artikel lesen | |
| 09.10. | NeOnc Technologies schließt Forschungsabkommen in den VAE und erweitert Vorstand | 1 | Investing.com Deutsch | ||
| 09.10. | NeOnc Technologies signs UAE research agreement, expands board | 2 | Investing.com | ||
| 09.10. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.10. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors | 1 | GlobeNewswire (USA) | ||
| 07.10. | New to The Street to Broadcast Tonight on Fox Business 10:30 PM PST Featuring NeOnc Technologies, FLOKI, XION, Sharps Technology, and Aeries Technology | 332 | ACCESS Newswire | NEW YORK CITY, NEW YORK / ACCESS Newswire / October 6, 2025 / New to The Street, one of America's longest-running business television brands, announces tonight's nationwide broadcast on Fox Business... ► Artikel lesen | |
| 06.10. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals | 1 | GlobeNewswire (USA) | ||
| 02.10. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board | 2 | GlobeNewswire (USA) | ||
| 29.09. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board | 2 | GlobeNewswire (USA) | ||
| 27.09. | New to The Street to Broadcast Saturday, September 27th Featuring NeOnc Pharma $NTHI and Other Innovative Companies | 479 | ACCESS Newswire | Bloomberg Television 6:30 PM ET as Sponsored Programming - With TV Commercials Debuting by Laser Photonics $LASE, Synergy CHC $SNYR, Sustainable Green Team $SGTM, and Acurx Pharmaceuticals $ACXP NEW... ► Artikel lesen | |
| 22.09. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies to Showcase Progress on Addressing Brain Cancer to 63 Million TV Households on "Health Uncensored with Dr. Drew" on the Lifetime Network on September 25, premiering nationwide at 8:00 a.m. ... | 1 | GlobeNewswire (USA) | ||
| 11.09. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.09. | FDA authorizes NeOnc to advance brain cancer drug to phase 2 trials | 1 | Investing.com |
1 2 3 4 Weiter >>
71 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NUVALENT | 105,88 | -1,97 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,56 | -0,13 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| QIAGEN | 40,380 | +2,38 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,170 | +8,45 % | Is Recursion Pharmaceuticals a Meme Stock? | ||
| BIONTECH | 83,05 | +0,06 % | Raus aus BioNTech? Rein in Evotec und Vidac Aktie? Was läuft da mit Johnson und Johnson? | Paukenschläge bei Biotechs: Partner Pfizer verkauft seine komplette Beteiligung am deutschen Biotech-Champion BioNTech. Sollten Anleger es genauso machen? Dagegen liefert Vidac Pharma mehr und mehr... ► Artikel lesen | |
| JANUX THERAPEUTICS | 28,800 | +0,73 % | Wolfe Research initiates Janux Therapeutics stock with Peerperform rating | ||
| PRAXIS PRECISION MEDICINES | 169,78 | +3,33 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Participate in Upcoming Fireside Chat | ||
| COGENT BIOSCIENCES | 36,770 | +5,97 % | COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know | ||
| OLEMA PHARMACEUTICALS | 23,190 | +5,36 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| IMMUNOVANT | 22,580 | -0,92 % | Immunovant, Inc. - 8-K, Current Report | ||
| ARCUTIS BIOTHERAPEUTICS | 29,460 | +7,89 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| EVOTEC | 5,206 | +0,58 % | Aktien KW 46 Aktien stolpern. Fallen sie nächste Woche? News. Hensoldt. RENK. Steyr Motors. Mutares. Bechtle. Cancom. Deutsche Rohstoff. Nagarro. SMA Solar. GFT. Nordex. Wacker-Neuson. Pyrum. Evotec. Deutsche Wohnen. LEG. TAG Immobilien. HomeToGo. Salzgit | Aktien: Woche enttäuschter Hoffnungen. Zuerst sah es so aus, als ob durch das Ende des Shutdowns die Aktienmärkte in Richtung neuer Rekorde laufen würden. Dazu kam es aber nicht. Zweifel an einer Zinssenkung... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 27,250 | +1,49 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
| IMMUNOME | 18,510 | +5,77 % | Varegacestat-Potenzial: Stephens erhöht Kursziel für Immunome auf 33 US-Dollar | ||
| MINERALYS THERAPEUTICS | 42,000 | +0,33 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen |
NEONC TECHNOLOGIES HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,33 % bei einem Aktienkurs von 5,870 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEONC TECHNOLOGIES HOLDINGS INC finden Sie auf Wallstreet Online.